Role of matrix metalloproteinases and their tissue inhibitor of metalloproteinases in myxomatous change of cardiac floppy valves

Pathology International

Volumn 57, Issue 5, 2007, Pages 251-259

  Togashi, Mayuko ^a   Tamura, Koichi ^a,b   Nitta, Takashi ^a   Ishizaki, Masamichi ^a   Sugisaki, Yuichi ^a,b   Fukuda, Yuh ^a  

^a NIPPON MEDICAL SCHOOL   (Japan)

^b NIPPON MEDICAL SCHOOL HOSPITAL   (Japan)

Author keywords

Floppy valve; Matrix metalloproteinases and their tissue inhibitors of metalloproteinases; Myxomatous change

Indexed keywords

GELATINASE A; GELATINASE B; TISSUE INHIBITOR OF METALLOPROTEINASE 1; TISSUE INHIBITOR OF METALLOPROTEINASE 2;

ADULT; AGED; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; ENZYME ACTIVITY; ENZYME REGULATION; FEMALE; FLOPPY VALVE; HEART VALVE; HUMAN; IMMUNOHISTOCHEMISTRY; MALE; MYXOMA; PRIORITY JOURNAL; PROTEIN EXPRESSION; VALVULAR HEART DISEASE; ZYMOGRAPHY;

AGED; DISEASE PROGRESSION; FEMALE; HEART NEOPLASMS; HEART VALVES; HUMANS; IMMUNOHISTOCHEMISTRY; MALE; MATRIX METALLOPROTEINASE 2; MATRIX METALLOPROTEINASE 9; MATRIX METALLOPROTEINASES; MIDDLE AGED; MYXOMA; TISSUE INHIBITOR OF METALLOPROTEINASE-1; TISSUE INHIBITOR OF METALLOPROTEINASE-2; TISSUE INHIBITOR OF METALLOPROTEINASES;

EID: 34247166284     PISSN: 13205463     EISSN: 14401827     Source Type: Journal    
DOI: 10.1111/j.1440-1827.2007.02096.x     Document Type: Article

References (30)

1. Rose AG. Etiology of valvular heart disease. Curr Opin Cardiol 1996; 11: 98-113.
2. Boudoulas H. Etiology of valvular heart disease. Expert Rev Cardiovasc Ther 2003; 1: 523-32.
3. Boudoulas H, Vavuranakis M, Wooley CF. Valvular heart disease: The influence of changing etiology on nosology. J Heart Valve Dis 1994; 3: 516-26.
4. Moriyama Y, Toyohira H, Koga M et al. Isolated aortic valve regurgitation due to degeneration of the valve leaflet: A clinical study. Nippon Kyobu Geka Gakkai Zasshi 1995; 43: 951-5.
5. Rabkin E, Aikawa M, Stone JR, Fukumoto Y, Libby P, Schoen FJ. Activated interstitial myofibroblasts express catabolic enzymes and mediate matrix remodeling in myxomatous heart valves. Circulation 2001; 104: 2525-32.
6. Fukuda Y, Ishizaki M, Okada Y, Seiki M, Yamanaka N. Matrix metalloproteinases and tissue inhibitor of metalloproteinase-2 in fetal rabbit lung. Am J Physiol Lung Cell Mol Phyiol 2000; 279: L555-L561.
7. Kunugi S, Fukuda Y, Ishizaki M, Yamanaka N. Role of MMP-2 in alveolar epithelial cell repair after bleomycin administration in rabbits. Lab Invest 2001; 81: 1309-18.
8. Yaguchi T, Fukuda Y, Ishizaki M, Yamanaka N. Immunohistochemical and gelatin zymography studies for matrix metalloproteinases in bleomycin-induced pulmonary fibrosis. Pathol Int 1998; 48: 954-63.
9. King BD, Clark MA, Baba N, Kilman JW, Wooley CF. 'Myxomatous' mitral valves: Collagen dissolution as primary defect. Circulation 1982; 66: 288-96.
10. Edwards JE. Chapter 11 Floppy mitral valve syndrome. Cardiovasc Clin 1988; 18: 249-71.
11. Tamura K, I-ida T, Fujii T, Tanaka S, Asano G. Floppy aortic valves without aortic root dilatation: Clinical, histological, and ultrastructural studies. J Nippon Med Sch 2002; 69: 355-64.
12. Tamura K, Fukuda Y, Ishizaki M, Masuda Y, Yamanaka N, Ferrans VJ. Abnormalities in elastic fibers and other connective-tissue components of floppy mitral valve. Am Heart J 1995; 129: 1149-58.
13. Ghomrasseni S, Dridi M, Gogly B et al. Anetoderma: An altered balance between metalloproteinases and tissue inhibitors of metalloproteinases. Am J Dermatopathol 2002; 24: 118-29.
14. Liang J, Liu E, Yu Y et al. Macrophage metalloelastase accelerates the progression of atherosclerosis in transgenic rabbits. Circulation 2006; 113: 1993-2001.
15. Halpert I, Sires UI, Roby J et al. Matrilysin is expressed by lipid-laden macrophage at sites of potential rupture in atherosclerotic lesions and localizes to areas of versican deposition, a proteoglycan substrate for the enzyme. Proc Natl Acad Sci USA 1996; 93: 9748-53.
16. Lambert E, Dasse E, Haye B, Petitfrere E. TIMPs as multifacial proteins. Clit Rer Oncol Hematol 2004; 49: 187-98.
17. Nagase H, Visse R, Murphy G. Structure and function of matrix metalloproteinases and TIMPs. Cardiovasc Res 2006; 69: 562-73.
18. Fukuda Y, Mochimaru H, Terasaki Y, Kawamoto M, Kudoh S. Mechanism of structural remodeling in pulmonary fibrosis. Chest 2001; 120: 41S-43S.
19. Nishimura K, Ikebuchi M, Kanaoka Y et al. Relationship between matrix metalloproteinases and tissue inhibitor of metalloproteinases in the wall of abdominal aortic aneurysms Int Angiol 2003; 22: 229-38.
20. Fujimoto N, Mouri N, Iwata K, Ohuchi E, Okada Y, Hayakawa T. A one-step sandwich enzyme immunoassay for human matrix metalloproteinase-2 (72-kDa gelatinase/type IV collagenase) using monoclonal antibodies. Clin Chim Acta 1993; 221: 91-103.
21. Okada Y, Gonoji Y, Naka K et al. Matrix metalloproteinase 9 (92-kDa gelatinase/type IV collagenase) from HT 1080 human fibrosarcoma cells. J Biol Chem 1992; 267: 21 712-19.
22. Sato H, Takino T, Okada Y et al. A matrix metalloproteinase expressed on the surface of invasive tumor cells. Nature 1994; 370: 61-5.
23. Seiki M. Membrane-type 1 matrix metalloproteinase: A key enzyme for tumor invasion. Cancer Lett 2003; 194: 1-11.
24. Soini Y, Satta J, Maatta M, Autio-Harmainen H. Expression of MMP-2, MMP-9, MT1-MMP, TIMP-1, and TIMP-2 mRNA in valvular lesions of the heart. J Pathol 2001; 194: 225-31.
25. Nagase H. Activation mechanisms of matrix metalloproteinases. Biol Chem 1997; 378: 151-60.
26. Boudoulas H, Wooley CF. Floppy mitral valve/mitral valve prolapse/mitral valvular regurgitation: Effects on the circulation. J Cardiol 2001; 37(Suppl I): 15-20.
27. Edep ME, Shirani J, Wolf P, Brown LD. Matrix metalloproteinase expression in nonrheumatic aortic stenosis. Cardiovasc Pathol 2000; 9: 281-6.
28. Koullias GJ, Korkilis DP, Ravichandran P, Psyrri A, Hatzaras I, Elefteriades JA. Tissue microarray detection of matrix metalloproteinases, in diseased tricuspid and bicuspid aortic valves with or without pathology of the ascending aorta. Eur J Cardiothorac Surg 2004; 26: 1098-103.
29. Kaden JJ, Vocke DC, Fischer CS et al. Expression and activity of matrix metalloproteinase-2 in calcific aortic stenosis. Z Cardiol 2004; 93: 124-30.
30. Satta J, Oiva J, Salo T et al. Evidence for an altered balance between matrix metalloproteinase-9 and its inhibitors in calcific aortic stenosis. Ann Thorac Surg 2003; 76: 681-8.